The moment she walked in, Kelowna skin cancer physician Dr. Ben Wiese knew this wasn’t a routine skin check. She was very ...

The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...

The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal ...

Known as the “great masquerader,” amelanotic melanoma may resemble a variety of benign lesions, thereby increasing diagnostic complexity.

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...

The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer and with participation from the ...

Unlocks path towards registrational Phase 3 trial planned to start in 2026Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine ...

The PHAROS trial supports Braftovi and Mektovi for BRAF V600E-mutant non-small cell lung cancer, showing improved survival and tolerability in treatment-naive patients. Comprehensive molecular testing ...

Aviation teaches that imprecision is not neutral -- it creates unnecessary harm ...

Marked regional and demographic variations persist in melanoma BRAF testing, and patients with BRAF-mutated tumours – particularly those with stage 2 disease – experience poorer five-year survival, ...

The discussion focuses on the unique treatment approach for BRAF V600E–mutant NSCLC, which differs from other oncogenic drivers such as EGFR or ALK that are typically treated with single-agent ...